Springer Nature brings trusted pharma intelligence into Claude

Integration to benefit users by increasing visibility and use of trusted content

London | New York | Berlin, 7 May 2026

AdisInsight brings together curated, evidence-linked intelligence spanning drug development, clinical trials, adverse drug reaction case reports, regulatory milestones including drug approvals, and the latest mergers, acquisitions and licensing opportunities.

Eligible institutional subscribers to both Claude and AdisInsight are now able to query and interact with AdisInsight directly within the Claude interface. The integration is delivered via a secure Model Context Protocol (MCP) server and Claude Connectors, allowing Claude to retrieve and ground responses in licensed AdisInsight content in real time, while preserving provenance, access controls and usage tracking.

By making trusted data available within familiar AI-enabled workflows, users are able to find, explore and apply relevant information quicker with full confidence in the quality, provenance and integrity of the underlying source material.

It also reflects Springer Nature's wider commitment to making sure content is visible and its usage able to be tracked and measured in an AI world.

Saskia Steinacker, Chief Product Officer at Springer Nature, said:

"This partnership reflects Springer Nature's approach to giving its customers greater choice in how they access and work with our content. It builds on our broader efforts to enable responsible access to high-quality research content in an AI world, while ensuring its usage can be tracked and measured."

Adding, Harald Wirsching, EVP, Data and Analytics Solutions at Springer Nature, said:

"It is important to us that our users have access to our trusted data without leaving or compromising their existing workflows. With the availability of AdisInsight within familiar AI-driven environments, we are enabling more seamless use of high-quality information across a range of life sciences workflows. This helps users interrogate data quickly and apply it confidently in real-world research, regulatory and business decision-making contexts."

Users can continue to use the AdisInsight web interface, engage with the AskAdis conversational search interface, Springer Nature's own generative AI assistant, connect AdisInsight data via APIs into internal systems and AI environments, or now access it through MCP-enabled integrations such as Claude. This flexible access model allows customers to choose the experience and workflow that best fits their needs.

Earlier this year, the publisher announced ARC3, a framework to give corporate customers clear, responsible and legal access to high-quality Springer Nature content, so published research can be safely integrated in AI-powered products and workflows. This includes AI systems for internal R&D purposes as well as for AI developers.

Springer Nature continues to take a responsible, researcher-led approach to AI, focused on enabling access to trusted content in the workflows researchers use. The publisher continues to selectively develop AI assists in the publishing process and explore partnerships, in line with its AI principles, to support research discovery, decision making and engagement. Alongside this, the publisher works actively within the research community to better understand evolving needs and drive forward industry conversations and policies around AI.

More around its approach to AI and strategy can be read in the publishers' latest annual report or on its AI hub.